| Page 170 | Aplastic Anemia and MDS International Foundation

Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.

Author(s): 
Bacher U, Haferlach C, Kröger N, Schnittger S, Kern W, Wiedemann B, Zander AR, Haferlach T
Primary Author: 
Bacher U
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Sep 2009

The rates of allogeneic stem cell transplantation (SCT) to treat the

Bone Marrow Diseases: 

Myelodysplastic syndromes: health care management considerations.

Author(s): 
Kogan AJ, Dunn JD
Primary Author: 
Kogan AJ
Journal Title: 
Manag Care
Original Publication Date: 
Nov 2009

Costs associated with treating cancers such as MDS are increasing as new medicines are developed and combination regimens gain hold. This trend presents an important challenge to MCOs who must respond to changing protocols and rising costs. Whereas the new oncology medications offer a unique opportunity to improve outcomes in patients with MDS, they also demand high financial outlay, which in turn necessitates adjustments in benefits programs.

Bone Marrow Diseases: 

Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.

Author(s): 
Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP
Primary Author: 
Jacobs NL
Journal Title: 
Am J Hematol
Original Publication Date: 
Mar 2010

The prognostic significance of the peripheral blood absolute

Bone Marrow Diseases: 

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

Author(s): 
Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, Gore SD, Ramos F, Beyne-Rauzy O, List A, McKenzie D, Backstrom J, Beach CL
Primary Author: 
Fenaux P
Journal Title: 
Br J Haematol
Original Publication Date: 
Feb 2010

In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most

Bone Marrow Diseases: 

Transplantation strategies for the management of patients with myelodysplastic syndromes.

Author(s): 
Meletis J, Terpos E
Primary Author: 
Meletis J
Journal Title: 
J BUON
Original Publication Date: 
Oct 2009

Allogeneic stem cell transplantation (SCT) is the only therapeutic modality at present that may be delivered with curative intent in

Bone Marrow Diseases: 

Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

Author(s): 
Loaiza-Bonilla A, Gore SD, Carraway HE
Primary Author: 
Loaiza-Bonilla A
Journal Title: 
Curr Opin Hematol
Original Publication Date: 
Mar 2010

PURPOSE OF REVIEW:

Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months.

Bone Marrow Diseases: